do not combine dpp-4 inhibitor with glp-1 receptor agonist guideline Mechanisms of dipeptidyl peptidase‐4 (DPP‐4) inhibitors, glucagon‐like DPP4 Inhibitor Mechanism of Action

Daily formulations like liraglutide reach steady state more quicklytypically within 2-3 daysbut require consistent daily administration

Diabetic kidney diseasea heterogenous disease with shared risk factors DKD, especially in people with T2D, is heterogenous in nature and driven by several risk factors

It directly stimulates pro-opiomelanocortin/cocaine-and-amphetamine-regulated transcript (POMC/CART) neurons and indirectly inhibits neuropeptide-Y/agouti-related protein (NPY/AgRP) neurons through GABA neurotransmission, reducing appetite and promoting weight loss [40]

Nissen and Lincoff suspect that reluctance will erode over time as more of these types of medications get approved for weight loss, particularly if the SELECT and SURMOUNT-MMO trials result in indications for atherosclerotic CVD